Clinical and Translational Research
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Oct 24, 2024; 15(10): 1280-1292
Published online Oct 24, 2024. doi: 10.5306/wjco.v15.i10.1280
Comprehensive assessment of the association between tumor-infiltrating immune cells and the prognosis of renal cell carcinoma
Guo-Hao Wei, Xi-Yi Wei, Ling-Yao Fan, Wen-Zheng Zhou, Ming Sun, Chuan-Dong Zhu
Guo-Hao Wei, Ling-Yao Fan, Wen-Zheng Zhou, Ming Sun, Chuan-Dong Zhu, Department of Oncology, The Second Hospital of Nanjing, Affiliated to Nanjing University of Chinese Medicine, Nanjing 210003, Jiangsu Province, China
Xi-Yi Wei, The State Key Laboratory of Reproductive, Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210003, Jiangsu Province, China
Author contributions: Wei GH wrote the article; Wei GH, Fan LY and Wei XY designed the experiments; Wei GH, Wei XY, Sun M and Zhou WZ analyzed data and contributed to the resources; Zhu CD supervised the study; All authors have read and approved the final manuscript.
Supported by The Medical Scientific Research Project of the Jiangsu Health Commission, China, No. M2020055; The Nanjing Medical Science and Technology Development Project, China, No. YKK22130; and The Postgraduate Research and Practice Innovation Program of Jiangsu Province, China, No. KYCX23_2105.
Conflict-of-interest statement: The authors declare no conflicts of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Chuan-Dong Zhu, MD, PhD, Assistant Professor, Chief Doctor, Department of Oncology, The Second Hospital of Nanjing, Affiliated to Nanjing University of Chinese Medicine, No. 1-1 Zhongfu District, Nanjing 210003, Jiangsu Province, China. zhucd@njucm.edu.cn
Received: July 4, 2024
Revised: August 7, 2024
Accepted: August 13, 2024
Published online: October 24, 2024
Processing time: 86 Days and 15.1 Hours
Core Tip

Core Tip: Renal cell carcinoma (RCC) is a prevalent form of renal cancer that typically arises subtly and is distinguished by its propensity for easy metastasis and poor prognosis. Patients with advanced RCC frequently exhibit low overall survival rates owing to the extensive spread of cancer. However, the recent advent of immunotherapy has resulted in an improvement in the median overall survival for all risk groups of patients, making it imperative to identify potential immune targets. Our research has led to the development of an immune risk assessment model that underscores the critical role of tumor-infiltrating immune cells-based immune models in the prognostic prediction and clinical management of RCC.